Current Treatment Landscape for KRASG12C-Mutated NSCLC

Opinion
Video

Narjust Florez, MD, discusses KRAS G12C mutated non-small cell lung cancer, a subset of KRAS mutations which comprises 14% of NSCLC cases.

Recent Videos
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Patrick Forde, MBBCh, with the Oncology Brothers presenting slides
Patrick Forde, MBBCh, with the Oncology Brothers presenting slides
Related Content
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC

Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC

Roman Fabbricatore;Ariana Pelosci
October 3rd 2024
Article

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Dato-DXd: A Path to Potential Approval in NSCLC

Dato-DXd: A Path to Potential Approval in NSCLC

ONCOLOGY Staff
September 29th 2024
Article

Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

Amivantamab Plus Chemo Approved by FDA in EGFR-Mutated NSCLC

Ariana Pelosci
September 19th 2024
Article

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

HER3-DXd Significantly Improves PFS Vs Chemo in Advanced EGFR+ NSCLC

Russ Conroy
September 17th 2024
Article

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.